Two non-steroidal anti-inflammatory drugs, tenoxicam and rofecoxib, were compared for the control of postoperative pain following surgical extraction of bilaterally and symmetrically impacted wisdom teeth performed under intravenous sedation and local anaesthesia. Thirty-five young fit adult patients received each analgesic treatment for four days in a randomized, crossover design. The results suggest statistically better pain relief for the selective COX-2 inhibitor rofecoxib compared to tenoxicam, a traditional NSAID. There were side-effects with both treatments. Abdominal discomfort was significantly more common following rofecoxib compared to tenoxicam. Both analgesics were acceptable to most participants in the trial.
Non-steroidal anti-inflammatory drugs (NSAIDs) have been successfully used for the management of postoperative pain 1 including the pain after surgical extraction of impacted wisdom teeth [2] [3] [4] . The mechanism of analgesic action is by the suppression of cyclo-oxygenase (COX) mediated production of prostaglandin E 2 , which is the major inflammatory prostaglandin activating the peripheral nociceptors. There are two COX isoforms, COX-1, primarily involved with homeostatic functions and COX-2, involved with inflammatory response. Most of the traditional NSAIDs are non-selective and have effects on both COX-1 and COX-2 enzyme isoforms. Many of the side-effects of NSAIDs, such as gastrointestinal effects, are attributed to inhibition of COX-1. Highly selective cyclo-oxygenase 2 iso-enzyme (COX-2) inhibitors have become available as analgesics and were introduced into clinical practice a few years ago. Drugs with tight binding to COX-2 and weak binding to COX-1 isoenzymes are more COX-2 selective and have a low COX-2/COX-1 IC50 ratio. The ratio for tenoxicam (Tilcotil™), the non-specific NSAID, is high and for rofecoxib (Vioxx™), a selective COX-2 inhibitor, the ratio is low.
There are a number of studies demonstrating the postoperative analgesic efficacy of selective COX-2 inhibitors, but many of them are single dose studies and the comparisons are mostly with placebo 5 . It is a widely held belief that selective COX-2 inhibitors are superior to traditional NSAIDs, particularly with regard to side-effects. At the time of designing this trial there were few published randomized controlled trials examining the use of COX-2 inhibitors for postoperative pain.
METHOD
Permission was obtained from the local ethics committee. Healthy adult patients (18 to 40 years, ASA 1-2) of both sexes scheduled to undergo surgical extractions of bilaterally and symmetrically impacted lower wisdom teeth, expected to have similar technical difficulty, were invited to take part in the trial. The procedures were to be done under intravenous sedation and local anaesthesia.
The study design was randomized, double-blinded and crossover (below).
Each patient underwent surgery on two separate occasions and on each occasion they received one of the two trial drugs (tenoxicam or rofecoxib). The trial drugs were dispensed by our hospital pharmacy in indistinguishable gelatine capsules inside sealed bottles.
Thirty-five patients consented (45 people were approached) and the crossover study had the following format:
Randomization was done for the side to be operated upon first (left or right) and the trial drug to be administered on each occasion (tenoxicam or rofecoxib). Randomization was by a random number generation method and was done independently by a pharmacist (who was not involved with the trial). For each subject, two coded bottles of "trial drugs" were delivered in a sealed envelope. Each bottle came with clear instructions about which side was to be operated upon first and which bottle of medication was to be used for which procedure. Both the patient and the observers were unaware of the nature of the drug until the completion of the trial.
The exclusion criteria were regular users of NSAIDs, history of intolerance to NSAIDs or midazolam (since they were to receive these drugs), pregnancy, severe asthma or significant medical problems (ASA3).
Patients were fasted for four hours for solid food and two hours for clear fluids. Upon arrival in the surgery, the envelope was opened and the side to be operated upon first and the trial medication bottle for that side was identified. All patients agreed with the randomized allocation of the side of operation. Prior to the procedure, patients were requested to record any pain; this was done by placing a mark on a 0-100 mm line, both for continuous pain and pain when opening the mouth. The maximum extent of mouth opening was measured, with the average of three measurements of inter-incisal distance being recorded. The trial drug was then administered. The patients received two capsules of the trial drug, either tenoxicam 20 mg (total dose 40 mg) or rofecoxib 25 mg (total dose 50 mg). Midazolam was given intravenously by one of the anaesthetists. When adequate sedation was established, the oral surgeon admini-stered the local anaesthetic (lignocaine 2% with 1/80,000 adrenaline). The local anaesthetic blocks and infiltrations included inferior dental, lingual and long buccal nerves for the lower wisdom teeth and posterior superior dental and greater palatine nerves for upper wisdom teeth. When adequate analgesia was established, surgery proceeded. The degree of difficulty of the surgical extraction was recorded by the surgeon at the end of the operation on a 1-3 scale (1 being mildly difficult, 2 moderately difficult and 3 very difficult).
At the end of surgery, pain scores were again recorded. The patients were then discharged and were instructed to take one capsule of the trial drug (rofecoxib 25 mg or tenoxicam 20 mg) every morning with food for the next three days. Subjects were also given tablets of paracetamol as rescue medication, to take 1 g every four hours if and when they required additional pain relief. A four-day diary for twice a day (8 pm and 8 am daily) recording was given to each subject. The diary was used to record pain scores (continuous pain and pain when they opened their mouth), rescue medication intake and any sideeffects including nausea, vomiting, dizziness, abdominal discomfort and poor appetite. Patients were instructed to mark the pain scores at the specified recording times and the rescue medication intake and symptom details for the preceding 12 hours.
The patients were seen by the oral surgeon on the first and fourth postoperative days and assessed for any surgical problems. Measurement of mouthopening was repeated at these times. Any signs of alveolar osteitis (dry socket) were noted on the fourth day by the surgeon.
The whole sequence was repeated for the second side. The minimum interval between the two treatments was three weeks.
We calculated the numbers required for the study as follows: from previous studies of analgesics following wisdom teeth extractions we have observed that the maximum pain occurs on the night of operation and the first postoperative morning 6 . We aimed to detect a 30% difference in the standard deviation in the mean pain scores on the night of operation, with P<0.05. We estimated that we would require 36 cases for 80% power and aimed to recruit 40 cases into the trial.
Upon completion of the trial, the drug code was broken and the two treatments were identified and data analysed using Stata program. A mixed model regression was used to analyse the paired continuous data, adjusting for the preoperative scores. A general estimating equations model was used for analysis of the side-effects. A paired t-test is the simplest form of mixed model and mixed models allow for different variances within and between subjects. Similarly, general estimating equations also allow the analysis of binary data that has within-subject (repeated measures for each treatment) and between-subject effects.
RESULTS
There were 11 males and 24 females participating in the trial. Two people opted out of the study after the first side and both received tenoxicam treatment on that occasion. One of these subjects (female) did not present for the second surgery and another (male) thought that the pain was unacceptable after the operation and hence withdrew from the trial. The data from these subjects' first procedure was used in the final analysis. The study population had an average age of 23.5 years (SD 4.3) and weight of 70.1 kg (SD 13.1). There were no differences between the two groups in respect of the duration of operation, surgical difficulty, amount of local anaesthetic used and dose of midazolam used for sedation.
All patients were able to satisfactorily complete the twelve-hourly VAS scores for pain and the rescue medication and symptom charts adequately. Continuous pain and pain on mouth-opening data were very similar throughout the study period and hence we combined the two for the purpose of analysis. Pain scores were approximately normally distributed, although slightly skewed, and hence were considered as continuous data for the purpose of analysis. Table 2 shows mean and SD values for pain and rescue medication intake recorded at twelve-hourly intervals (twice a day). Mixed model regression analysis showed a mean difference of pain of 4.0 mm between the two treatments, with 95% CI, 1.7 to 6.4 (P=0.001). Rofecoxib gave better pain scores compared to tenoxicam in the postoperative period. Rescue medication intake (paracetamol) showed no significant differences between the two treatments (difference of 0.1g, 95% CI, 0 to 0.2, P=0.051).
Restriction of mouth-opening (trismus) was considered an indication of the functional restriction due to the pain and inflammation after surgery. The data are given in Table 3 . There was significant restriction of mouth opening both on the first and fourth days following both the drugs, but this was less severe after rofecoxib than after tenoxicam on the first day (difference 4.0 mm, 95% CI 0.9 to 7.0, P=0.01).
Patients' reports of side-effects are given in Table  4 . Nausea and dizziness were common during the first 24 hours. Abdominal discomfort and poor appetite were of concern to many patients, particularly on the second and third days. Even though the incidence of some of these side-effects appeared high with rofecoxib treatment, statistically significant differ- ence was seen only with abdominal discomfort (OR 6.9, 95% CI 2.3 to 20.6).
It is of note that in spite of the high incidence of pain and other unwanted side-effects, most patients rated the treatments as good or satisfactory. Only three patients in the tenoxicam treatment (9%) and one patient in the rofecoxib treatment (3%) found the analgesic regimen unacceptable.
DISCUSSION
We conducted a randomized crossover trial comparing two NSAIDs. We did not use a placebo group since there is good evidence that both traditional NSAIDs and selective COX-2 inhibitors are better than placebo for treatment of postoperative pain 7, 8 . Our study suggested that rofecoxib (selective COX-2 inhibitor) gave significantly better pain control (P=0.001) than tenoxicam (traditional NSAID) after surgical extractions of third molar teeth ( Table 2 ). The amount of rescue medication used was not significantly different between the two groups. Caution is required before concluding that rofecoxib is a better analgesic than tenoxicam. One possible reason for the difference in analgesia could be that rofecoxib was used in a relatively larger and thus more efficacious dose. The doses used in the study, (rofecoxib 50 mg then 25 mg daily and tenoxicam 40 mg then 20 mg daily for the next three days) followed the commercial reality of tenoxicam being available in 20 mg and rofecoxib in 25mg strengths. There is some indication that these are equipotent doses since the recommended average daily quantities (ADQ) for rofecoxib is 25 mg and for tenoxicam is 20 mg 9 . Another reason to use this strength of the drugs was that these are the preparations available to practitioners.
We believe that the restriction in mouth-opening, seen with both treatments, is due to tissue swelling and muscle spasm, consequent on pain and inflammation, which inevitably follows third molar extrac-tions. The better analgesia for rofecoxib was perhaps matched by less functional impairment as shown by less restriction of mouth-opening with this drug (Table 3) in comparison to tenoxicam, on the first postoperative day (P=0.01).
These differences in pain scores and mouthopening are likely to be due to the drug effects because of the fact that the intake of rescue medication (paracetamol) did not differ between the two treatments (P>0.05). One of the possible criticisms of this study is the twelve hourly scoring of pain and rescue medication intake. However, our previous experience with requests for record keeping at shorter intervals for four days were not successful in a similar population. In the interests of compliance and acceptable burden of documentation, the twice daily recording regimen was adopted.
Our study looked at side-effects such as nausea, vomiting, dizziness, abdominal discomfort and poor appetite. Nausea and dizziness (light headedness) were common on the day of operation and may have been partially due to the intravenous midazolam used at the time of the surgery. Vomiting was rare and occurred only once (each) in two patients. Of concern to the patients was the occurrence of abdominal discomfort and poor appetite, mostly appearing on the second and third postoperative days. The incidence of abdominal discomfort was significantly more (OR 6.9, 95% CI 2.3-20.6) when rofecoxib was the treatment drug ( Table 4 ). One of the perceived advantages of selective COX-2 inhibitors is based on the published reduced incidence of adverse gastrointestinal effects compared to traditional NSAIDs. These studies were done in older patients with chronic conditions such as osteoarthritis or rheumatoid arthritis 10, 11 and looked at only major gastrointestinal side-effects such as bleeding following long-term use of the drugs 12 .
The incidence of alveolar osteitis (dry socket) was very high in this study. With tenoxicam it was 26% and it was 34% with rofecoxib. The reported incidence of alveolar osteitis following third molar surgery varies greatly in the literature and can be as high as 30% following surgical extractions of third molar teeth 13 . There are multiple causes which contribute towards this pathology which presents with intense pain usually after the second or third postoperative day. Smoking and the use of oral contraceptives are known to increase the incidence of dry socket formation, but there is no clear evidence that the use of NSAIDs increases this complication. We feel that the high incidence in our study ( prescribe prophylactic antibiotic (which is known to reduce the incidence). The possible role of the study drugs in dry socket occurrence is uncertain. Only two patients in our study admitted to regular smoking and hence smoking was unlikely to have been the cause of the alveolar osteitis in the present study.
Most of the studies to date on the use of rofecoxib for postoperative pain control have looked at single dose administrations, and have not looked at minor side-effects 5, 14 . Our study suggests that minor gastrointestinal side-effects are greater with the specific COX-2 inhibitor rofecoxib compared to the traditional NSAID tenoxicam. The patient population (young, healthy), type of surgery (wisdom teeth extractions) and short duration of medication intake (four days), all could have contributed toward this observation. Our study had low power for the detection of differences in binary outcomes, such as incidence of side-effects.
Although we have shown differences in outcome between the two treatments, most patients in our trial (over 90%) rated the analgesic regimens as good or satisfactory. Only three patients in the tenoxicam treatment (9%) and one patient in the rofecoxib treatment (3%) found the analgesic regimen unacceptable. The reason for this was pain and no-one commented adversely on the side-effects. This high satisfaction rate could have been related to low (or realistic) expectations in the community from which the subjects were drawn, that pain and other problems following wisdom teeth extraction are relatively common.
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